Disease ID | Disease name | Source of annotation with TGFBR2 | OMIM link | Number of associated genes | genes |
---|---|---|---|---|---|
133239 | ESOPHAGEAL CANCER | OMIM, HUMSAVAR | link to OMIM | 7 | TGFBR2, DCC, DLEC1, RNF6, DEC1, WWOX, LZTS1 |
PS609192 | LOEYS-DIETZ SYNDROME | ClinVar, OMIM, HUMSAVAR | link to OMIM | 5 | TGFB3, SMAD3, TGFBR2, TGFB2, TGFBR1 |
PS120435 | COLORECTAL CANCER, HEREDITARY NONPOLYPOSIS | ClinVar, OMIM, HUMSAVAR | link to OMIM | 7 | TGFBR2, MSH6, PMS2, MLH3, EPCAM, MLH1, MSH2 |
PS607086 | AORTIC ANEURYSM, FAMILIAL THORACIC | ClinVar, OMIM, HUMSAVAR | link to OMIM | 7 | TGFBR2, ACTA2, TGFBR1, MYH11, MYLK, PRKG1, MFAP5 |
Download the gene annotation in CSV format
KEGG pathway | KEGG ID | KEGG IC |
---|---|---|
TGF-beta signaling pathway | hsa04350 | 6.41 |
Chronic myeloid leukemia | hsa05220 | 6.48 |
Pancreatic cancer | hsa05212 | 6.56 |
Colorectal cancer | hsa05210 | 6.52 |
MAPK signaling pathway | hsa04010 | 4.63 |
Pathways in cancer | hsa05200 | 3.98 |
Transcriptional misregulation in cancer | hsa05202 | 5.21 |
Chagas disease (American trypanosomiasis) | hsa05142 | 5.99 |
Adherens junction | hsa04520 | 6.26 |
Hippo signaling pathway | hsa04390 | 5.37 |
Endocytosis | hsa04144 | 4.92 |
FoxO signaling pathway | hsa04068 | 5.63 |
Osteoclast differentiation | hsa04380 | 5.64 |
HTLV-I infection | hsa05166 | 4.59 |
Cytokine-cytokine receptor interaction | hsa04060 | 4.67 |
REACTOME pathway | REACTOME ID | REACTOME IC |
---|---|---|
Signal Transduction | R-HSA-162582 | 1.78 |
Diseases of signal transduction | R-HSA-5663202 | 4.89 |
SMAD2/3 Phosphorylation Motif Mutants in Cancer | R-HSA-3304356 | 10.4 |
Signaling by TGF-beta Receptor Complex in Cancer | R-HSA-3304351 | 9.98 |
TGFBR2 Kinase Domain Mutants in Cancer | R-HSA-3645790 | 10.98 |
TGFBR2 MSI Frameshift Mutants in Cancer | R-HSA-3642279 | 11.98 |
Loss of Function of TGFBR2 in Cancer | R-HSA-3642278 | 10.98 |
Signaling by TGF-beta Receptor Complex | R-HSA-170834 | 6.81 |
Downregulation of TGF-beta receptor signaling | R-HSA-2173788 | 8.28 |
Loss of Function of SMAD2/3 in Cancer | R-HSA-3304349 | 10.18 |
TGFBR1 KD Mutants in Cancer | R-HSA-3656532 | 10.18 |
TGFBR1 LBD Mutants in Cancer | R-HSA-3656535 | 10.98 |
Loss of Function of TGFBR1 in Cancer | R-HSA-3656534 | 10.18 |
TGF-beta receptor signaling activates SMADs | R-HSA-2173789 | 7.98 |
TGF-beta receptor signaling in EMT (epithelial to mesenchymal transition) | R-HSA-2173791 | 8.98 |
SMAD2/3 MH2 Domain Mutants in Cancer | R-HSA-3315487 | 10.18 |
Disease | R-HSA-1643685 | 3.33 |
GO term | GO ID | GO IC |
---|---|---|
cytokine receptor binding | GO:0005126 | 4.14 |
signaling receptor activity | GO:0038023 | 2.49 |
purine ribonucleoside triphosphate binding | GO:0035639 | 2.22 |
transforming growth factor beta receptor binding | GO:0005160 | 5.81 |
cytokine binding | GO:0019955 | 5.21 |
enzyme binding | GO:0019899 | 2.27 |
ribonucleoside binding | GO:0032549 | 2.22 |
molecular transducer activity | GO:0060089 | 2.32 |
small molecule binding | GO:0036094 | 1.89 |
binding | GO:0005488 | 0.18 |
signal transducer activity | GO:0004871 | 2.28 |
nucleotide binding | GO:0000166 | 1.96 |
heterocyclic compound binding | GO:1901363 | 1.06 |
nucleoside phosphate binding | GO:1901265 | 1.96 |
transforming growth factor beta binding | GO:0050431 | 6.97 |
cation binding | GO:0043169 | 1.4 |
mitogen-activated protein kinase kinase kinase binding | GO:0031435 | 6.85 |
receptor signaling protein activity | GO:0005057 | 4.76 |
type III transforming growth factor beta receptor binding | GO:0034714 | 8.35 |
growth factor binding | GO:0019838 | 4.89 |
ion binding | GO:0043167 | 1.36 |
transmembrane receptor protein serine/threonine kinase activity | GO:0004675 | 6.91 |
protein serine/threonine kinase activity | GO:0004674 | 3.64 |
transferase activity | GO:0016740 | 1.95 |
nucleoside binding | GO:0001882 | 2.21 |
purine nucleoside binding | GO:0001883 | 2.22 |
protein kinase activity | GO:0004672 | 3.27 |
purine nucleotide binding | GO:0017076 | 2.19 |
metal ion binding | GO:0046872 | 1.41 |
ATP binding | GO:0005524 | 2.43 |
kinase activity | GO:0016301 | 2.93 |
SMAD binding | GO:0046332 | 5.45 |
kinase binding | GO:0019900 | 3.32 |
type I transforming growth factor beta receptor binding | GO:0034713 | 7.44 |
protein kinase binding | GO:0019901 | 3.44 |
adenyl nucleotide binding | GO:0030554 | 2.4 |
carbohydrate derivative binding | GO:0097367 | 2.03 |
organic cyclic compound binding | GO:0097159 | 1.05 |
catalytic activity | GO:0003824 | 1.05 |
transforming growth factor beta receptor activity, type II | GO:0005026 | 9.05 |
transferase activity, transferring phosphorus-containing groups | GO:0016772 | 2.77 |
transforming growth factor beta-activated receptor activity | GO:0005024 | 7.44 |
glycosaminoglycan binding | GO:0005539 | 4.42 |
phosphotransferase activity, alcohol group as acceptor | GO:0016773 | 3.08 |
transmembrane signaling receptor activity | GO:0004888 | 2.57 |
adenyl ribonucleotide binding | GO:0032559 | 2.41 |
transmembrane receptor activity | GO:0099600 | 2.53 |
protein binding | GO:0005515 | 0.46 |
receptor signaling protein serine/threonine kinase activity | GO:0004702 | 5.23 |
purine ribonucleotide binding | GO:0032555 | 2.2 |
receptor binding | GO:0005102 | 2.43 |
transmembrane receptor protein kinase activity | GO:0019199 | 5.32 |
purine ribonucleoside binding | GO:0032550 | 2.22 |
ribonucleotide binding | GO:0032553 | 2.19 |
receptor activity | GO:0004872 | 2.32 |